Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer
(2022)
Presentation / Conference Contribution
Bruce, I., Pang, L., Poole, A., & Fraser, J. (2022, November). Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer. Poster presented at Society for Endocrinology BES 2022, Harrogate
Neuroendocrine castrate resistant prostate cancer (NE-CRPC) is a lethal CRPC subtype that arises as prostate cancer cells transdifferentiate to neuroendocrine cells, evading the potent selective pressure of androgen deprivation therapies (ADT). Curre... Read More about Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer.